FDA Denies Emergency Use Authorization for New COVID-19 Drug

The Food and Drug Administration (FDA) headquarters in White Oak, Md., on Aug. 29, 2020. Andrew Kelly/Reuters

The U.S. Food and Drug Administration (FDA) has declined emergency use authorization for a lenzilumab monoclonal antibody drug to treat COVID-19, according to the developer of the drug.

Humanigen sought emergency use authorization for the medication to treat newly hospitalized COVID-19 patients. The company filed its petition with the drug regulator in May.